CAD 1.0
(5.26%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 | - CAD | 0.0% |
2023 | - CAD | -100.0% |
2022 | 2.46 Million CAD | -31.67% |
2021 | 3.61 Million CAD | 2171.7% |
2020 | 159 Thousand CAD | 0.0% |
2019 | - CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
2015 | - CAD | 0.0% |
2014 | - CAD | 0.0% |
2013 | - CAD | 0.0% |
2012 | - CAD | 0.0% |
2011 | - CAD | 0.0% |
2010 | - CAD | 0.0% |
2009 | - CAD | 0.0% |
2008 | - CAD | 0.0% |
2007 | - CAD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | - CAD | 0.0% |
2024 Q1 | - CAD | 0.0% |
2024 Q3 | - CAD | 0.0% |
2024 Q4 | - CAD | 0.0% |
2023 Q3 | - CAD | 0.0% |
2023 Q4 | - CAD | 0.0% |
2023 FY | - CAD | -100.0% |
2023 Q1 | - CAD | -100.0% |
2023 Q2 | - CAD | 0.0% |
2022 Q4 | 2.46 Million CAD | -14.37% |
2022 FY | 2.46 Million CAD | -31.67% |
2022 Q1 | 3.31 Million CAD | -8.14% |
2022 Q2 | 2.96 Million CAD | -10.67% |
2022 Q3 | 2.88 Million CAD | -2.77% |
2021 Q1 | 99 Thousand CAD | -37.74% |
2021 FY | 3.61 Million CAD | 2171.7% |
2021 Q2 | 67 Thousand CAD | -32.32% |
2021 Q3 | 34 Thousand CAD | -49.25% |
2021 Q4 | 3.61 Million CAD | 10523.53% |
2020 Q1 | - CAD | 0.0% |
2020 FY | 159 Thousand CAD | 0.0% |
2020 Q4 | 159 Thousand CAD | 0.0% |
2020 Q2 | - CAD | 0.0% |
2020 Q3 | - CAD | 0.0% |
2019 FY | - CAD | 0.0% |
2019 Q1 | - CAD | 0.0% |
2019 Q2 | - CAD | 0.0% |
2019 Q3 | - CAD | 0.0% |
2019 Q4 | - CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2018 Q4 | - CAD | 0.0% |
2018 Q3 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2016 Q1 | - CAD | 0.0% |
2015 Q2 | - CAD | 0.0% |
2015 FY | - CAD | 0.0% |
2015 Q1 | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2015 Q3 | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2014 Q4 | - CAD | 0.0% |
2013 Q4 | - CAD | 0.0% |
2013 FY | - CAD | 0.0% |
2013 Q1 | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2012 FY | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2011 FY | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2010 FY | - CAD | 0.0% |
2009 FY | - CAD | 0.0% |
2008 FY | - CAD | 0.0% |
2007 FY | - CAD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Appili Therapeutics Inc. | 8.18 Million CAD | 100.0% |
Eupraxia Pharmaceuticals Inc. | 13.78 Million CAD | 100.0% |
Microbix Biosystems Inc. | 6.64 Million CAD | 100.0% |
Medicenna Therapeutics Corp. | - CAD | NaN% |
Satellos Bioscience Inc. | - CAD | NaN% |
Oncolytics Biotech Inc. | 423 Thousand CAD | 100.0% |
Sernova Corp. | 136.12 Thousand CAD | 100.0% |